Background-Hypertension or aortic stenosis causes pressure overload, which evokes hypertrophic myocardial growth.
I
ncreased blood pressure, which occurs in approximately onethird of the global adult population, has become a major public health problem. 1 Aortic stenosis is commonly caused by atherosclerotic disease, which damages and stiffens the aortic valve, thereby reducing orifice area. 2 Both hypertension and aortic stenosis can result in significant left ventricular (LV) pressure overload, which evokes myocardial hypertrophy. 1, 2 There is widespread agreement that sustained hypertrophy with increased extracellular matrix (ECM) deposition is an important intermediate step leading to heart failure (HF). 3, 4 Growing clinical and experimental evidence suggests that suppression/reversal of the hypertrophic process may be beneficial even if pressure overload remains present. 5, 6 In humans from the onset of cardiac hypertrophy to the end stage of HF, it usually takes relatively long time. This leaves a large time window, in which a patient displaying early cardiac hypertrophy could be treated to slow or even reverse the progresFTY-720 is a synthetic sphingosine analogue, recently approved by the Food and Drug Administration as a drug (named Gilenya) for treating relapsing multiple sclerosis. FTY-720 undergoes phosphorylation by sphingosine kinases, and phosphorylated FTY-720 competes with sphingosine 1-phosphate (S1P) to bind to G-protein-coupled S1P receptors (S1PRs) to regulate diverse biological activities. [7] [8] [9] We have previously demonstrated that FTY-720 is able to prevent the initiation of cardiac hypertrophy. 10 However, clinically it is difficult to anticipate the onset of cardiac hypertrophy; therefore, more useful treatments would aim to reverse/alleviate existing hypertrophy. To this end, in experiments reported here we investigated whether FTY-720 can reverse existing hypertrophy/fibrosis and its mechanism of action.
We discovered that FTY-720 profoundly reverses existing hypertrophy/fibrosis through negative regulation of nuclear factor of activated T-cells (NFAT) activity in cardiomyocytes through G i -signaling and reduction of periostin expression in the ECM, which renders a favorable milieu for myocytes, leading to improved cardiac performance. Our study provides new insights into the potential medical use of FTY-720 or its analogues for treating hypertrophic/fibrotic heart disease associated with hypertension, atherosclerotic/rheumatic valvular lesion, and cardiomyopathy.
Methods
Detailed methods echocardiography, hemodynamic analysis, histology, immunoblot analyses, quantitative polymerase chain reaction, immunocytochemistry, luciferase assay, and Affymetrix gene expression array are available in the online-only Data Supplement.
Animal Models of Pressure Overload and FTY-720 Treatment
Pressure overload by transverse aortic constriction (TAC) was used to induce cardiac hypertrophy in male C57/Bl6 mice (8-10 weeks old). One week after surgery, TAC-or sham-operated mice were randomized into different cohorts for intraperitoneal injection of FTY-720 (10 μg/g per day) or vehicle for further 2 weeks. To determine whether FTY-720 requires G i -signaling for limiting hypertrophy, after 1 week of TAC, C57/Bl6 mice were treated with FTY-720 (10 μg/g per day) alone, or along with PTX, or PTX alone (30 ng/g per every 3 days for 2 weeks). Hypertrophic responses at the end of the treatment were analyzed by echocardiography, hemodynamic analysis, and biochemical analysis.
Echocardiography and Hemodynamic Analysis
Mice were anesthetized with Avertin (200 mg/kg) via intraperitoneal injection. Transthoracic M-mode echocardiographic recordings were performed using an Acuson Sequoia C256 system (Siemens). Three measurements taken at end-systole and end-diastole were averaged to calculate intraventricular septal (IVS) thickness, LV posterior wall (PW) thickness, LV end-diastolic dimension, LV end-systolic Figure 1 . FTY-720 reverses cardiac hypertrophy and interstitial fibrosis caused by pressure overload. A, Heart weight/tibia length (HW/TL) ratios and B, measurements of mean cross-sectional area of cardiomyocytes (scale bar, 20 μm) demonstrate that transverse aortic constriction (TAC) increased, whereas FTY-720 reduced cardiac hypertrophy. C, Quantitative polymerase chain reaction analysis of atrial natriuretic peptide (ANP) and regulator of calcineurin 1 variants 4 (RCAN1.4). The data are normalized to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH). D, Masson's trichrome staining (scale bar, 50 μm) shows that FTY-720 remarkably reduced TAC-induced fibrosis. Quantification of the relative area of fibrosis is expressed as percentage fibrosis. E, Quantification of immunostaining of heart sections with anti-Mac-3 and antineutrophil antibodies indicates increased populations of macrophages and neutrophils in TAC-stressed ventricular myocardium, whereas FTY-720 treatment ameliorated this TAC-provoked leukocyte infiltration. n=8 to 12 per group, data are presented as mean±SEM.
dimension, and fractional shortening (%). In vivo hemodynamic analysis was performed using a pressure volume system (Millar Instruments). We used a 1.4F pressure-volume catheter (SPR-839) following a protocol described previously. 10 Pressure-volume loops and a variety of hemodynamic parameters were measured to evaluate cardiac contractile and diastolic functions.
Neonatal Rat Cardiomyocytes and Human Embryonic Cardiomyocytes
Neonatal rat cardiomyocytes (NRCMs) were isolated from 1-to 2-day-old Sprague-Dawley rats and plated in culture medium at a field density of 2×10 6 cells per well for treatments and subsequent analyses. The University of Manchester research ethics committee approved the collection of human tissue for cell culture. Human embryonic cardiomyocytes were prepared from spontaneous aborted human fetuses (9-12 weeks) and isolated human embryonic cardiomyocytes were cultured at a density of 2×10 6 cells per well for various treatments and analyses.
Neonatal Rat Cardiac Fibroblasts and Human Adult Cardiac Fibroblasts
Neonatal rat cardiac fibroblasts (NRCFs) were prepared from the hearts of Sprague-Dawley rats at 1 to 2 days old. Human adult cardiac fibroblasts were purchased from Promo Cell Co and cultured in conditioned medium supplemented with insulin (5 μg/mL) and basic fibroblast growth factor (1 ng/mL).
Affymetrix Gene Expression Array
Gene expression arrays for sham hearts and TAC hearts treated with or without FTY-720 were performed with Mouse Genome 430 2.0 array chip (Affymetrix). The details of procedure and data analysis are provided in the Methods section in the online-only Data Supplement.
Data Analysis
Data distribution normality was examined by Kolgomorov-Smirnov test. One-way or 2-way ANOVA followed by Bonferonni post hoc tests were used for statistical comparisons among multiple groups, as appropriate. Comparisons between 2 groups were performed using Student t test. P values <0.05 were considered statistically significant. Data are expressed as mean±SEM.
Results

FTY-720 Reverses Existing Cardiac Hypertrophy and Fibrosis
One week of TAC was sufficient to induce steady cardiac hypertrophy ( Figure I in the online-only Data Supplement). At this time point, FTY-720 or vehicle was administered for 2 weeks while continuation of TAC. Under the similar pressure gradients (30 mm Hg), TAC-mice receiving FTY-720 manifested less hypertrophy than mice receiving vehicle, evidenced by a significant decrease in heart weight/tibia length ratio and a substantial reduction in cross-sectional area of TAC/FTY-720 cardiomyocytes with respect to the TAC/vehicle cardiomyocytes ( Figure 1A and 1B) . This diminution in hypertrophy was confirmed by quantitative polymerase chain reaction analysis of hypertrophic biomarker genes. Transcript expression of atrial natriuretic peptide and regulator of calcineurin 1 variants 4 was significantly downregulated in the TAC/FTY-720 hearts ( Figure 1C ). Cardiac remodeling was also greatly improved in the FTY-720-treated hearts. Masson's trichrome staining barely detected interstitial fibrosis in the TAC/FTY-720 hearts ( Figure 1D ). Leukocyte infiltration was analyzed by immunohistochemistry that revealed very few infiltrating macrophages and neutrophils in TAC/FTY-720 myocardium ( Figure 1E ). Moreover, we found that even compared with 1-week TAC hearts, FTY-720-treated hearts exhibited less hypertrophic remodeling ( Table I in (A and B) . C and D, Chamber dimensions at end-systole and end-diastole were enlarged in TAC-stressed hearts, whereas ventricular chamber of FTY-720-treated hearts at both stages became smaller. E, Cardiac function indexed by FS % was measured at 1 and 3 weeks of TAC, indicating that fractional shortening (FS%) was decreased by TAC stress, but improved by 2 weeks of FTY-720 treatment. F, TAC for 3 weeks induced a prominent rightward shift of the pressure-volume loops, whereas FTY-720 treatment brought the loops leftward. n=8 to 12 per group, data are presented as mean±SEM. dPW, posterior wall; dIVS, intraventricular septal; LVEDD, LV enddiastolic dimension; and LVESD, LV end-systolic dimension. 
FTY-720 Improves Cardiac Performance
Reduced cardiac hypertrophy by FTY-720 treatment was substantiated by echocardiographic analysis. Compared with the TAC-only group, dPW and dIVS at end-diastole were consistently decreased in the TAC/FTY-720 ventricles ( To further assess the effect of FTY-720 on cardiac function, invasive hemodynamic analysis was performed. Pressurevolume loops were measured before and during transient inferior vena cava occlusion. The sham condition had the most leftward pressure-volume loops, whereas 3 weeks of TAC induced a prominent rightward shift of the loops, while FTY-720 treatment brought this shift back ( Figure 2F ), indicating 3 weeks of TAC caused a chamber dilation, and FTY-720 treatment ameliorated this deterioration. Notably, ejection fraction (%) and end-systolic elastance were significantly higher, whereas LV end-diastolic volume and end-diastolic pressure were decreased by FTY-720 treatment (Table) . FTY-720 was reported to cause a transient slowing in heart rate in human subjects; 11 however, we did not detect slowed heart rate at the time of recording. Also, FTY-720 did not alter blood pressure and LV peak pressure (Table) .
FTY-720 Attenuates NFAT Activity
We next investigated the mechanistic action of FTY-720 at the cellular and molecular levels. FTY-720-treated NRCMs showed obviously smaller cell surface area than NRCMS treated with phenylephrine (PE) only ( Figure Led by the observed downregulation of regulator of calcineurin 1 variants 4 mRNA level in the TAC/FTY-720 heart, we next examined whether FTY-720 has an ability to regulate NFAT activity. Immunofluorescence staining demonstrated that PE stimulation caused NFAT nuclear translocation, whereas FTY-720 treatment mobilized its movement from the nucleus to the cytoplasm ( Figure 3A and 3B). Knockdown of Pak1 by shPak1 potentiated PE-induced NFAT nuclear accumulation, but under these conditions lacking Pak1, FTY-720 was unable to reverse this effect ( Figure 3A and 3B) . Also, FTY-720 failed τ indicates time constant of relaxation normalized to heart rate; BP, blood pressure; CO, cardiac output; dP/dtmax, peak rate of pressure rise; dP/dtmin, peak rate of pressure decline; Ea, arterial elastance; Ees, LV end-systolic elastance (stiffness); EF, ejection fraction; HR, heart rate; LV, left ventricular; MSW, preload recruitable stroke work; Ped, end-diastolic pressure; Pes, end-systolic pressure; SV, stroke volume; Ved, end-diastolic volume; and Ves, end-systolic volume; n=8 to 12 per group, data are presented as mean±SEM.
to block NFAT nuclear translocation in NRCMs expressing constitutively active calcineurin ( Figure 3C ). Together, these results suggest that FTY-720 does not have a direct effect on calcineurin and that the reversal of hypertrophy occurs by Pak1 activation, which is likely through negative regulation of NFAT activity.
FTY-720 Targets G i -Signaling
FTY-720 is able to interact both G q -and G i -coupled receptors depending on biological context. 12,13 G q stimulation of cardiac hypertrophy is well documented, 14, 15 and thus by inference we asked that FTY-720 may work through G i -dependent signaling to exert its antihypertrophic function. First, we tested whether FTY-720 phosphorylation by sphingosine kinases is a precondition for its antihypertrophic function. Western blotting demonstrated that FTY-720 induced Pak1 phosphorylation, whereas SPHK inhibitor 2 blocked it ( Figure 4A ), suggesting conversion to FTY-720-P is required for its function. To determine whether FTY-720-induced Pak1 phosphorylation depends on its interaction with S1PR, we pretreated NRCMs with of S1P with increasing doses followed by 1-hour treatment of FTY-720. As shown, FTY-720 alone induced marked Pak1 phosphorylation, whereas pretreatment with S1P blocked this phosphorylation with a significant effect at 200 nmol/L ( Figure 4A ). Next, we found that FTY-720 induced whereas PTX blocked Pak1 phosphorylation ( Figure 4B ). To translate this finding to a scenario relevant in humans, the above experiment was performed in human fetal cardiomyocytes (HFCMs). We found that PTX counteracted FTY-720-induced Pak1 phosphorylation in HFCMs ( Figure 4B ). Furthermore, we observed that HFCMs receiving PTX treatment had an increased atrial natriuretic peptide expression comparable with that in PE-treated cells and significantly more than that in FTY-720-treated HFCMs ( Figure 4C ).
Next, we tested our hypothesis in a pressure-overloaded mouse model. Mice undergoing TAC for 1 week were then administered with FTY-720 for 2 weeks with or without PTX. In agreement with in vitro data, we found that PTX treatment offset the protective effect of FTY-720, causing hypertrophy comparable with that induced by 3 weeks of TAC in control animals ( Figure 4D and 4E) . Echocardiographic analysis corroborated changes in these treatment groups (Figure 4F-4H ; Table II in the online-only Data Supplement). The beneficial effect of FTY-720 on cardiac performance was also diminished in the presence of PTX ( Figure 4H) . Notably, treatment with PTX alone did not cause any change in cardiac structure and function in sham mice, also TAC-stressed mice receiving PTX only did not display further hypertrophy (Figure 4D-4H ; Table II in the online-only Data Supplement). Taken together, our data demonstrate that FTY-720 works through PTXsensitive G i -coupled receptors to activate Pak1, thereby antagonizing NFAT activity for reversing hypertrophy.
Periostin Is Involved in Reduced Fibrotic Response After FTY-720 Treatment
In view of our observations that FTY-720 efficiently ameliorated TAC-induced interstitial fibrosis, we then performed Affymetrix gene array analysis of TAC hearts to probe the mechanism underpinning this beneficial effect of FTY-720. Of 45 000 analyzed transcripts, 56 genes were significantly altered (P<0.05) as a result of both TAC and FTY-720 treatment. Using the DAVID (Database for Annotation, Visualization and Integrated Discovery) functional annotation tool, we found that a large set of these differentially expressed genes fell into a biological category involving ECM organization or inflammation response, such as periostin, collagens, thrombospondin-4, interleukin-6, pleiotrophin, and tumor necrosis factor receptor superfamily member 11b ( Figure 5 ; Table III in the online-only Data Supplement). Among these altered genes periostin was prominent; its mRNA expression was significantly increased with hypertrophic remodeling (5.4-fold increase; P<0.01) but decreased by FTY-720 treatment (nearly 3-fold decrease; P<0.01). A, Representative fluorescent images show the cytoplasmic-nuclear localization of endogenous NFATc4 in neonatal rat cardiomyocytes (NRCMs) infected with AdshPak1 or Ad-shC2 followed by treatment with phenylephrine (PE)±FTY-720, which demonstrate FTY-720 inhibited PE-induced NFAT nuclear retention, whereas such inhibitory effects were eliminated in NRCMs with Pak1 knockdown. Red staining is for NFAT, blue for visualizing the nuclei, arrows point to cytoplasmic NFAT; arrowheads show nuclear localization of NFAT (scale bar, 20 μm). B, These results were quantified from ≈500 infected cardiomyocytes per group and presented as the percentage of cells with nuclear-NFAT. C, Immunostaining of NFAT4c was also applied to NRCMs infected by Ad-CnA with or without FTY-720. Ad-LacZ was used as a control virus. Quantitative data are presented as the percentage of cells expressing nuclear-NFAT. n=5 per group, data are presented as mean±SEM.
To corroborate the array results, we examined protein expression of periostin. The periostin level in sham-operated hearts was undetectable, but in TAC hearts it was markedly induced; however, this induction was reduced on FTY-720 treatment ( Figure 6A ). Furthermore, we detected that expression of collagen 1α2, 3α1, and 5α2 was significantly induced by TAC stress, but decreased by FTY-720 treatment ( Figure 6B ). Next, we examined whether FTY-720 could directly affect periostin expression in cardiac fibroblasts. NRCFs and human adult cardiac fibroblasts were incubated with angiotensin II (Ang II) with or without FTY-720. After 24-hour incubation, we detected considerably higher periostin expression in response to Ang II in both cell types, whereas FTY-720 decreased its expression ( Figure 6C ). Transforming growth factor (TGF)-β signaling can profoundly influence ECM deposition through inducing expression of profibrotic proteins. [16] [17] [18] Although transcript expression of major TGF-β family members seemed not to be altered in the gene array analysis, we extended our investigation to the examination of TGF-β activation. We determined that expression of activated TGF-β1 (25 kDa) and Smad 2 phosphorylation was substantially increased on TAC stress but decreased in response to FTY-720 treatment ( Figure 6D ). Moreover, we used a TGF-β responsive luciferase-reporter system to determine whether FTY-720 is able to block TGF-β activation. NRCFs were cocultured with TGF-β responsive reporter cells, which contained a plasminogen activator inhibitor-1 promoter fused to the luciferase-reporter gene. 19 After 24-hour treatment of Ang II with or without FTY-720, we detected a significantly higher luciferase activity in response to Ang II alone, whereas in the presence of FTY-720 the luciferase activity was much lower, indicating the presence of an FTY-720 inhibition of TGF-β responsiveness ( Figure 6E ). Periostin is known to be a TGF-β-inducible matrix protein; conversely, periostin itself has important roles in TGF-β activation and collagen production. [20] [21] [22] [23] We then investigated whether periostin affects TGF-β responsiveness in cardiac fibroblasts. Periostin was knocked down by si-periostin in NRCFs, which were then exposed to Ang II for 48 hours. We detected that expression of activated TGF-β1 and Smad 2 phosphorylation was appreciably increased in response to Ang II stimulation, but Ang II failed to induce TGF-β activation when periostin was absent ( Figure 6F ). Furthermore, we found that periostin knockdown diminished Ang II-induced gene expression of collagen 1α2 and 5α2 ( Figure 6F ).
Finally, we tested whether FTY-720 induced periostin reduction involves Pak1 signaling. Interestingly, we observed that FTY-720 was unable to reduce Ang II-induced periostin expression in NRCFs with Pak1 knockdown ( Figure VA and VB in the online-only Data Supplement). In contrast, overexpression of Pak1 in NRCFs was sufficient to decrease periostin expression by Ang II stimulation ( Figure VB in the online-only Data Supplement). NFAT activity was also examined in NRCFs, but we found that FTY-720 had no effect on Ang II-induced NFAT activity ( Figure VC in the onlineonly Data Supplement). Moreover, excessive amount of S1P was shown to prevent Pak1 phosphorylation by FTY-720 in NRCFs; however, PTX had no effect on this phosphorylation ( Figure VD and VE in the online-only Data Supplement). These data suggest that FTY-720 likely requires S1PRs and Pak1 for its antifibrotic effect; however, signaling system used by FTY-720 for reducing fibrotic response in cardiac fibroblasts seems different because it operates in cardiomyocytes for antagonizing hypertrophy.
Discussion
In this study, we identified a new dual-mechanism system used by FTY-720 for treating hypertrophic/fibrotic heart disease. The major findings of this study are as follows: (1) phosphorylated FTY-720 through G i -coupled S1PRs conveys antihypertrophic signals involving Pak1/NFAT signaling in cardiomyocytes; (2) periostin seems to be a primary effector of FTY-720 in the ECM. By this dual-mechanism system FTY-720 reverses hypertrophy, reduces the fibrotic response, restores ECM integrity, and improves cardiac performance ( Figure 7) .
FTY-720, G i -Coupled Receptors, and NFAT Signaling in Cardiomyocyte Hypertrophy
Being part of the G-protein-coupled receptor family, S1P receptors (S1PRs) can activate different signaling cascades by coupling with heterotrimeric G-proteins.
12,13 S1P 1 receptor selectively couples to G i -proteins, whereas S1P 3 is a promiscuous receptor available for all major G-protein subtypes.
12,13 Cardiomyocytes express both S1P 1 and S1P 3 .
24,25
Here, we found that exposure of NRCMs or C57/Bl6 mice to PTX rendered FTY-720 ineffective at reducing hypertrophic response to either PE or TAC. This effect was similar in the context of human cardiomyocytes. Moreover, excessive S1P was found to block FTY-720 effect on Pak1 phosphorylation. Thus, we believe that FTY-720 inhibits hypertrophy likely through G i -coupled S1PRs and this mechanism can be used by cardiomyocytes across different species. The NFAT family of transcription factors is a nodal control point of the cardiac hypertrophic response. Our data suggest that FTY-720 seems to be related to the negative regulation of NFAT transcriptional responsiveness through signaling involving Pak1. To determine whether the suppression of NFAT activity is directly responsible for antihypertrophic effect of FTY-720, future experiments are needed to test FTY-720 effect in mouse models with targeted inhibition or activation of NFAT signaling.
FTY-720 and Periostin in Fibrotic Response
ECM components constitute a fibrous skeleton for maintaining overall ventricular geometries and proper myocyte organization. Long-standing pressure overload associated with hypertension, valvular disease, and cardiomyopathy all induce remodeling of the ECM. 26 In other words, these major forms of heart diseases often develop greater hypertrophy with overabundant fibrosis and ventricular disobedience. As described above, we successfully identified periostin, which was significantly altered in correlation to TAC stress and FTY-720 treatment. Periostin is a secreted ECM protein with minimum expression in adult ventricles at baseline, but it is dramatically re-expressed largely by cardiac fibroblasts after pressure overload or myocardial infarction. 21, 27 As a crucial adhesion molecule periostin is important for regulating ECM integrity and modulating hypertrophy through its ability to bind with multiple ECM components and integrins. 27 In genetic modification studies, periostin knockout (Pn −/− ) resulted in reduced fibrosis and hypertrophy after pressure overload, 28, 29 whereas periostin-overexpressing transgenic mice developed spontaneous hypertrophy with aging. 28, 29 Akin to these findings, we observed that periostin expression was massively increased by TAC stress, but its expression was decreased with a concomitant reduction in fibrosis and hypertrophy after FTY-720 treatment. Moreover, FTY-720 treatment led to a reduction in Ang II-induced periostin expression, whereas periostin knockdown resulted in blunted TGF-β activation and decreased collagen expression in cardiac fibroblasts. This finding is consistent with previous observations that not only is periostin induced by TGF-β but also periostin itself can activate TGF-β signaling. 20, 22 It has been demonstrated in lung and skin that fibrotic remodeling can occur from activation of latent TGF-β in the ECM rather than from accrued transcription. 30, 31 Consistently, we demonstrated that the mechanical force of pressure overload activated latent TGF-β, whereas FTY-720 inhibited its activation. Given that periostin is an important activator of the TGF-β signaling pathway, we hypothesize that reduced periostin by FTY-720 treatment is possibly attributable to blunted TGF-β activation, which in turn further downregulates periostin expression. By modulating this signaling feedback loop, FTY-720 reduces fibrotic response and restores ECM integrity.
Apart from matricellular proteins, we also found a set of cytokines responding to FTY-720 treatment, such as interleukin-6, pleiotrophin, and tumor necrosis factor receptor superfamily member 11b. Notably, interleukin-6 is a potent hypertrophic factor signaling through gp130 in response to pressure overload. 32 The ability of FTY-720 to suppress interleukin-6 expression was also reported in an atherosclerosis mouse model. 33 It is plausible that reduction of interleukin-6 or other cytokines and matrix proteins may participate in some extent to the high capacity of FTY-720 to reserve cardiac hypertrophy and associated fibrosis.
FTY-720 and Cardiac Performance
One important criterion for antihypertrophic drug is its capability of improving cardiac performance. Our data indicate that FTY-720 likely ameliorates functional deterioration evident by increased fractional shortening % and ejection fraction %, whereas on another point, arterial elastance was decreased by FTY-720. Given similarity in pressure gradient and no changes in heart rate, it could suggest a possibility that FTY-720 may affect systemic resistance, which gives rise to a lower net afterload. Although we did not observe any alterations in blood pressure in various treated groups, whether FTY-720 has effects on vascular tone was not investigated directly in this study. It is plausible that FTY-720 may work through interactions with both myocardium and vasculatures, resulting in improved cardiac function. Another interesting point is the Figure 7 . Proposed model shows the reversal of hypertrophy and fibrosis by FTY-720 through a dual-mechanism system involving negative regulation of NFAT (nuclear factor of activated T-cells) activity in cardiomyocytes and diminution of periostin expression in the extracellular matrix (ECM). S1P indicates sphingosine 1-phosphate; and TGF-β, transforming growth factor-β.
effect of FTY-720 on diastolic function. Although FTY-720 significantly reduced fibrotic response with an early sign of improvement of compliance, however, some major diastolic parameters, like τ and dP/dt min , remained unchanged. This incongruity may be related to the fact that in mice the amount of fibrosis does not always generally reflect the extent of diastolic stiffness in left ventricles. Future study using a chronic and severe TAC model (9-16 weeks) may provide a better evaluation for FTY-720 efficacy on both systolic and diastolic functions.
Clinical Potential and Future Study
A growing number of clinical and experimental studies have discovered elevated periostin expression in the hearts of atherosclerotic and rheumatic valvular heart disease, hypertrophic cardiomyopathy, and Marfan syndrome, 34, 35 suggesting an important role for periostin in the pathogenesis of these heart diseases. Suggested by our current findings, further investigations are needed to test FTY-720 efficacy in animal models mimicking these hypertrophic/fibrotic heart diseases. Another interesting point is that some efforts have been made to alleviate ECM remodeling by interfering with the TGF-β pathway during the past few years 6 ; however, pleiotropic effects of TGF-β render its clinical use somewhat difficult. It seems, therefore, that inhibition of periostin by FTY-720 may be more optimal than global TGF-β blockage. Although we here demonstrated that Pak1 is involved in FTY-720-induced periostin diminution in cardiac fibroblasts, however, action mechanisms underlying FTY-720 reduced fibrotic response, with regards to G-protein subtype and downstream molecules are largely unknown and required further investigations.
Conclusion
Reversal of hypertrophy and fibrosis by FTY-720 might occur through a dual-mechanism system involving negative regulation of NFAT activity in cardiomyocytes and diminution of periostin expression in the ECM. Two mechanisms can work in a reinforcing manner leading to better cardiac performance. Overall, this study shows promise for the clinical use of FTY-720 or its analogues for hypertrophic/fibrotic heart disease.
